Abstract
The p53 master regulatory network provides for the stress-responsive direct control of a vast number of genes in humans that can be grouped into several biological categories including cell-cycle control, apoptosis and DNA repair. Similar to other sequence-specific master regulators, there is a matrix of key components, which provide for variation within the p53 master regulatory network that include p53 itself, target response element sequences (REs) that provide for p53 regulation of target genes, chromatin, accessory proteins and transcription machinery. Changes in any of these can impact the expression of individual genes, groups of genes and the eventual biological responses. The many REs represent the core of the master regulatory network. Since defects or altered expression of p53 are associated with over 50% of all cancers and greater than 90% of p53 mutations are in the sequence-specific DNA-binding domain, it is important to understand the relationship between wild-type or mutant p53 proteins and the target response elements. In the words of the legendary detective Sherlock Holmes, it is ‘Element ary, my dear Mr. Watson.’
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL . (1999). Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 18: 5954–5958.
Ahn J, Prives C . (2001). The C-terminus of p53: the more you learn the less you know. Nat Struct Biol 8: 730–732.
An W, Kim J, Roeder RG . (2004). Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 117: 735–748.
Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE et al. (2005). A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 280: 26776–26787.
Ashur-Fabian O, Avivi A, Trakhtenbrot L, Adamsky K, Cohen M, Kajakaro G et al. (2004). Evolution of p53 in hypoxia-stressed Spalax mimics human tumor mutation. Proc Natl Acad Sci USA 101: 12236–12241.
Avivi A, Ashur-Fabian O, Amariglio N, Nevo E, Rechavi G . (2005). p53-a key player in tumoral and evolutionary adaptation: a lesson from the Israeli blind subterranean mole rat. Cell Cycle 4: 368–372.
Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G et al. (2003). p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3: 387–402.
Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A et al. (2006). iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38: 1133–1141.
Blandino G, Levine AJ, Oren M . (1999). Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18: 477–485.
Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H et al. (2006a). MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66: 5104–5110.
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC et al. (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591–602.
Bond GL, Menin C, Bertorelle R, Alhorpuro P, Aaltonen LA, Levine AJ . (2006b). MDM2 SNP309 Accelerates colorectal tumour formation in women. J Med Genet 43: 950–952.
Brachmann RK, Vidal M, Boeke JD . (1996). Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci USA 93: 4091–4095.
Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B et al. (2001). p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 20: 3573–3579.
Cho Y, Gorina S, Jeffrey PD, Pavletich NP . (1994). Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations [see comments]. Science 265: 346–355.
Contente A, Dittmer A, Koch MC, Roth J, Dobbelstein M . (2002). A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat Genet 30: 315–320.
Deppert W, Gohler T, Koga H, Kim E . (2000). Mutant p53: ‘gain of function’ through perturbation of nuclear structure and function? J Cell Biochem Suppl 35: 115–122.
Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A et al. (2006). Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10: 191–202.
el-Deiry WS . (1998). Regulation of p53 downstream genes. Semin Cancer Biol 8: 345–357.
el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B . (1992). Definition of a consensus binding site for p53. Nat Genet 1: 45–49.
Espinosa JM, Emerson BM . (2001). Transcriptional Regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 8: 57–69.
Espinosa JM, Verdun RE, Emerson BM . (2003). p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell 12: 1015–1027.
Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P et al. (1995). A simple p53 functional assay for screening cell lines, blood and tumors. Proc Natl Acad Sci USA 92: 3963–3967.
Freeman J, Schmidt S, Scharer E, Iggo R . (1994). Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein. EMBO J 13: 5393–5400.
Funk WD, Pak DT, Karas RH, Wright WE, Shay JW . (1992). A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12: 2866–2871.
Gomes NP, Bjerke G, Llorente B, Szostek SA, Emerson BM, Espinosa JM . (2006). Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev 20: 601–612.
Hamroun D, Kato S, Ishioka C, Claustres M, Beroud C, Soussi T . (2006). The UMD TP53 database and website: update and revisions. Hum Mutat 27: 14–20.
Ho J, Benchimol S . (2003). Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ 10: 404–408.
Ho JS, Ma W, Mao DY, Benchimol S . (2005). p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol 25: 7423–7431.
Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M . (2002). Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277: 3247–3257.
Hoh J, Jin S, Parrado T, Edington J, Levine AJ, Ott J . (2002). The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci USA 99: 8467–8472.
Hupp TR, Lane DP . (1994). Allosteric activation of latent p53 tetramers. Curr Biol 4: 865–875.
Inga A, Monti P, Fronza G, Darden T, Resnick MA . (2001). p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Oncogene 20: 501–513.
Inga A, Nahari D, Velasco-Miguel S, Friedberg EC, Resnick MA . (2002a). A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions. Oncogene 21: 5704–5715.
Inga A, Reamon-Buettner SM, Borlak J, Resnick MA . (2005). Functional dissection of sequence-specific NKX2-5 DNA binding domain mutations associated with human heart septation defects using a yeast-based system. Hum Mol Genet 14: 1965–1975.
Inga A, Resnick MA . (2001). Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants. Oncogene 20: 3409–3419.
Inga A, Storici F, Darden TA, Resnick MA . (2002b). Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol 22: 8612–8625.
Ishioka C, Frebourg T, Yan YX, Vidal M, Friend SH, Schmidt S et al. (1993). Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 5: 124–129.
Ito M, Yuan CX, Malik S, Gu W, Fondell JD, Yamamura S et al. (1999). Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. Mol Cell 3: 361–370.
Johnson RA, Ince TA, Scotto KW . (2001). Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 276: 27716–27720.
Johnston M . (1987). A model fungal gene regulatory mechanism: the GAL genes of Saccharomyces cerevisiae. Microbiol Rev 51: 458–476.
Kaeser MD, Iggo RD . (2002). Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 99: 95–100.
Kannan K, Kaminski N, Rechavi G, Jakob-Hirsch J, Amariglio N, Givol D . (2001). DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. Oncogene 20: 3449–3455.
Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R et al. (2003). Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100: 8424–8429.
Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE et al. (2006). Structural basis of DNA recognition by p53 tetramers. Mol Cell 22: 741–753.
Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M et al. (2001). Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 21: 1297–1310.
Lefstin JA, Yamamoto KR . (1998). Allosteric effects of DNA on transcriptional regulators. Nature 392: 885–888.
Levine AJ, Hu W, Feng Z . (2006). The P53 pathway: what questions remain to be explored? Cell Death Differ 13: 1027–1036.
Li B, Lee MY . (2001). Transcriptional regulation of the human DNA polymerase delta catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1. J Biol Chem 276: 29729–29739.
Lim YP, Lim TT, Chan YL, Song AC, Yeo BH, Vojtesek B et al. (2006). The p53 knowledgebase: an integrated information resource for p53 research. Oncogene [Epub ahead of print].
Liu S, Mirza A, Wang L . (2004). Generation of p53 target database via integration of microarray and global p53 DNA-binding site analysis. Methods Mol Biol 281: 33–54.
Lohr D, Venkov P, Zlatanova J . (1995). Transcriptional regulation in the yeast GAL gene family: a complex genetic network. FASEB J 9: 777–787.
MacIsaac KD, Fraenkel E . (2006). Practical strategies for discovering regulatory DNA sequence motifs. PLoS Comput Biol 2: e36.
May P, May E . (1999). Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18: 7621–7636.
McKinney K, Mattia M, Gottifredi V, Prives C . (2004). p53 linear diffusion along DNA requires its C terminus. Mol Cell 16: 413–424.
McLure KG, Lee PW . (1998). How p53 binds DNA as a tetramer. EMBO J 17: 3342–3350.
Menendez D, Inga A, Resnick MA . (2006a). The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes. Mol Cell Biol 26: 2297–2308.
Menendez D, Krysiak O, Inga A, Krysiak B, Resnick MA, Schonfelder G . (2006b). A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc Natl Acad Sci USA 103: 1406–1411.
Menendez D, Inga A, Snipe J, Krysiak O, Schönfelder G, Resnick MA . (2007). A SNP in a half-binding site creates p53 and estrogen receptor control of VEGFR1. Mol Cell Biol in press.
Miled C, Pontoglio M, Garbay S, Yaniv M, Weitzman JB . (2005). A genomic map of p53 binding sites identifies novel p53 targets involved in an apoptotic network. Cancer Res 65: 5096–5104.
Minsky N, Oren M . (2004). The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol Cell 16: 631–639.
Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ et al. (1999). Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13: 2490–2501.
Nagaich AK, Appella E, Harrington RE . (1997). DNA bending is essential for the site-specific recognition of DNA response elements by the DNA binding domain of the tumor suppressor protein p53. J Biol Chem 272: 14842–14849.
Nagaich AK, Zhurkin VB, Durell SR, Jernigan RL, Appella E, Harrington RE . (1999). p53-induced DNA bending and twisting: p53 tetramer binds on the outer side of a DNA loop and increases DNA twisting. Proc Natl Acad Sci USA 96: 1875–1880.
O'Farrell TJ, Ghosh P, Dobashi N, Sasaki CY, Longo DL . (2004). Comparison of the effect of mutant and wild-type p53 on global gene expression. Cancer Res 64: 8199–8207.
Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P . (2002). The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607–614.
Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J et al. (2006). The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12: 1157–1167.
Prives C, Hall PA . (1999). The p53 pathway. J Pathol 187: 112–126.
Qian H, Wang T, Brachmann RK . (2002). Not all p53 DNA binding sites are created equal. Proceeding of the American Association for Cancer Research 43: 1141.
Reis AM, Cheo DL, Meira LB, Greenblatt MS, Bond JP, Nahari D et al. (2000). Genotype-specific Trp53 mutational analysis in ultraviolet B radiation- induced skin cancers in Xpc and Xpc Trp53 mutant mice. Cancer Res 60: 1571–1579.
Resnick-Silverman L, St Clair S, Maurer M, Zhao K, Manfredi JJ . (1998). Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev 12: 2102–2107.
Resnick MA, Inga A . (2003). Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 100: 9934–9939 . Epub 2003 Aug 8.
Rubbi CP, Milner J . (2003). p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage. EMBO J 22: 975–986.
Shiraishi K, Kato S, Han SY, Liu W, Otsuka K, Sakayori M et al. (2004). Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 279: 348–355.
Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F et al. (1998). Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393: 229–234.
Storici F, Durham CL, Gordenin DA, Resnick MA . (2003). Chromosomal site-specific double-strand breaks are efficiently targeted for repair by oligonucleotides in yeast. Proc Natl Acad Sci USA 100: 14994–14999.
Storici F, Lewis LK, Resnick MA . (2001). In vivo site-directed mutagenesis using oligonucleotides. Nat Biotechnol 19: 773–776.
Storici F, Resnick MA . (2006). The delitto perfetto approach to in vivo site-directed mutagenesis and chromosome rearrangements with synthetic oligonucleotides in yeast. Methods Enzymol 409: 329–345.
Szak ST, Mays D, Pietenpol JA . (2001). Kinetics of p53 binding to promoter sites in vivo. Mol Cell Biol 21: 3375–3386.
Tan T, Chu G . (2002). p53 Binds and activates the xeroderma pigmentosum DDB2 gene in humans but not mice. Mol Cell Biol 22: 3247–3254.
Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G . (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19: 1092–1100.
Thornborrow EC, Patel S, Mastropietro AE, Schwartzfarb EM, Manfredi JJ . (2002). A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes. Oncogene 21: 990–999.
Thukral SK, Lu Y, Blain GC, Harvey TS, Jacobsen VL . (1995). Discrimination of DNA binding sites by mutant p53 proteins. Mol Cell Biol 15: 5196–5202.
Tokino T, Thiagalingam S, el-Deiry WS, Waldman T, Kinzler KW, Vogelstein B . (1994). p53 tagged sites from human genomic DNA. Hum Mol Genet 3: 1537–1542.
Tomso DJ, Inga A, Menendez D, Pittman GS, Campbell MR, Storici F et al. (2005). Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. Proc Natl Acad Sci USA 102: 6431–6436.
Vogelstein B, Lane D, Levine AJ . (2000). Surfing the p53 network. Nature 408: 307–310.
Vousden KH . (2000). p53: death star. Cell 103: 691–694.
Wallberg AE, Yamamura S, Malik S, Spiegelman BM, Roeder RG . (2003). Coordination of p300-mediated chromatin remodeling and TRAP/mediator function through coactivator PGC-1alpha. Mol Cell 12: 1137–1149.
Wang L, Wu Q, Qiu P, Mirza A, McGuirk M, Kirschmeier P et al. (2001). Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J Biol Chem 276: 43604–43610.
Wang Y, Schwedes JF, Parks D, Mann K, Tegtmeyer P . (1995). Interaction of p53 with its consensus DNA-binding site. Mol Cell Biol 15: 2157–2165.
Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T et al. (2006). A global map of p53 transcription-factor binding sites in the human genome. Cell 124: 207–219.
Weinberg RL, Veprintsev DB, Bycroft M, Fersht AR . (2005). Comparative binding of p53 to its promoter and DNA recognition elements. J Mol Biol 348: 589–596.
Xu H, el-Gewely MR . (2001). P53-responsive genes and the potential for cancer diagnostics and therapeutics development. Biotechnol Annu Rev 7: 131–164.
Xu H, El-Gewely MR . (2003). Differentially expressed downstream genes in cells with normal or mutated p53. Oncol Res 13: 429–436.
Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B . (1999). Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA 96: 14517–14522.
Zhai W, Comai L . (2000). Repression of RNA polymerase I transcription by the tumor suppressor p53. Mol Cell Biol 20: 5930–5938.
Zhang X, Krutchinsky A, Fukuda A, Chen W, Yamamura S, Chait BT et al. (2005). MED1/TRAP220 exists predominantly in a TRAP/ Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. Mol Cell 19: 89–100.
Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH et al. (2000). Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 1 4: 981–993.
Acknowledgements
We appreciate the critical comments on the paper by Chris Halweg and Tom Darden. This work was partially supported by a grant from the Italian Association for Cancer Research, AIRC (to AI) and intramural research funds from NIEHS. Jennifer Jordan is supported by a Department of Defense Breast Cancer Research Program Predoctoral Traineeship Award (BC051212).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Menendez, D., Inga, A., Jordan, J. et al. Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson. Oncogene 26, 2191–2201 (2007). https://doi.org/10.1038/sj.onc.1210277
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210277
Keywords
This article is cited by
-
The novel p53 target TNFAIP8 variant 2 is increased in cancer and offsets p53-dependent tumor suppression
Cell Death & Differentiation (2017)
-
Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation
International Journal of Peptide Research and Therapeutics (2016)
-
p53 gene discriminates two ecologically divergent sister species of pine voles
Heredity (2015)
-
p53 regulates the transcription of its Δ133p53 isoform through specific response elements contained within the TP53 P2 internal promoter
Oncogene (2010)
-
The expanding universe of p53 targets
Nature Reviews Cancer (2009)